Stories

Bob Herman Jun 29
SaveSave story

The rising opposition to Mylan's leaders

Mylan CEO Heather Bresch (Alex Brandon / AP)

An investor uprising is starting to bubble over at Mylan, which has been under fire for hiking the prices of EpiPens and other drugs. Mylan released the vote tallies from its June 22 shareholder meeting, and the picture wasn't pretty.

Why it matters: It's a prime example of the megaphone that activist investors have today, and of the tone deafness that some in the pharmaceutical industry have toward their business operations.